Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of BGM0504 versus tirzepatide for weight control in Chinese adults with moderate to severe obesity without diabetes
CTR20251037Phase 2Active
- Sponsor
- Borray New Creation Biopharmaceutical Technology
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BGM0504, tirzepatide in obesity, Overweight, sponsored by Borray New Creation Biopharmaceutical Technology. Started Apr 2025; status: active.
02
Drugs
BGM0504tirzepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20251037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251037.